Erlotinib-induced pustular eruption.
The epidermal growth factor receptor (EGFR) inhibitor erlotinib was found to significantly improve overall survival, time to progression, and cancer-related symptoms in locally advanced or metastatic non small cell lung carcinoma (NSCLC). Unfortunately, cutaneous side effects are not rare, the most common one being a follicular acneiform eruption. As it has been observed a positive correlation between rash severity and objective tumor response, it is critical for dermatologists early distinguish it from rashes carrying a different prognosis and needing a different management.
Cusano
F
F
Unit of Dermatology, G. Rummo Hospital, Benevento, Italy. francesco.cusano2@tin.it
Ferrara
G
G
Barletta
E
E
Ingordo
V
V
D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy; D000279:Administration, Cutaneous; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D000069347:Erlotinib Hydrochloride; D004917:Erythromycin / Q000627:therapeutic use; D005782:Gels; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D005782:Gels; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D004917:Erythromycin; D000069347:Erlotinib Hydrochloride